Classification and clinical value of three immune subtypes of ovarian cancer based on transcriptome data

References

• Alcaraz-Sanabria A, Baliu-Pique M, Saiz-Ladera C, Rojas K, Manzano A, Marquina G, Casado A, Cimas FJ, Perez-Segura P, Pandiella A, et al. 2019. Genomic signatures of immune activation predict outcome in advanced stages of ovarian cancer and basal-like breast tumors. Front Oncol. 9:1486.
   PubMed Web of Science ®Google Scholar
• Althaf MM, El Kossi M, Jin JK, Sharma A, Halawa AM. 2017 Dec. Human leukocyte antigen typing and crossmatch: a comprehensive review. World J Transplant. 24(7):339–348.
   Google Scholar
• An Y, Yang Q. 2020 Feb. MiR-21 modulates the polarization of macrophages and increases the effects of M2 macrophages on promoting the chemoresistance of ovarian cancer. Life Sci. 1(242):117162.
   Google Scholar
• Andersson E, Poschke I, Villabona L, Carlson JW, Lundqvist A, Kiessling R, Seliger B, Masucci GV. 2016. Non-classical HLA-class I expression in serous ovarian carcinoma: correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. Oncoimmunology. 5:e1052213.
   PubMed Web of Science ®Google Scholar
• Arora T, Mullangi S, Lekkala MR. 2021. Ovarian cancer. Treasure Island (FL): StatPearls.
   Google Scholar
• Bland JM, Altman DG. 1998 Dec. Survival probabilities (the Kaplan-Meier method). BMJ. 5(317):1572.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018 Nov. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. 2011 Jun. Integrated genomic analyses of ovarian carcinoma. Nature. 29(474):609–615.
   Google Scholar
• Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD. 2016 Nov. Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer. 22(16):911.
   Google Scholar
• De La Motte Rouge T, Corne J, Cauchois A, Le Boulch M, Poupon C, Henno S, Rioux-Leclercq N, Le Pabic E, Laviolle B, Catros V, et al. 2019 Dec. Serum CD95L level correlates with tumor immune infiltration and is a positive prognostic marker for advanced high-grade serous ovarian cancer. Mol Cancer Res. 17:2537–2548.
   Web of Science ®Google Scholar
• Feng E, Liang T, Wang X, Du J, Tang K, Wang X, Wang F, You G. 2019 Feb. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples. J Neuroinflammation. 12(16):33.
   Google Scholar
• Guo L, Zhang Y, Yang Z, Peng H, Wei R, Wang C, Feng M. 2019 Feb. Tunneling nanotubular expressways for ultrafast and accurate M1 macrophage delivery of anticancer drugs to metastatic ovarian carcinoma. ACS Nano. 26(13):1078–1096.
   Google Scholar
• Halle MK, Sodal M, Forsse D, Engerud H, Woie K, Lura NG, Wagner-Larsen KS, Trovik J, Bertelsen BI, Haldorsen IS, et al. 2021 May. A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. Br J Cancer. 124:1690–1698.
   Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. 2013 Jan. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 16(14):7.
   Google Scholar
• Hazra A, Gogtay N. 2016 May–Jun. Biostatistics series module 3: comparing groups: numerical variables. Indian J Dermatol. 61:251–260.
   PubMed Web of Science ®Google Scholar
• Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. 2020 Jun. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol. 157:810–816.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP. 2007 Nov. Subclass mapping: identifying common subtypes in independent disease data sets. PloS one. 21(2):e1195.
   Google Scholar
• Jessmon P, Boulanger T, Zhou W, Patwardhan P. 2017 May. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 17:427–437.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. 2018 Oct. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 24:1550–1558.
   PubMed Web of Science ®Google Scholar
• Kather JN, Horner C, Weis CA, Aung T, Vokuhl C, Weiss C, Scheer M, Marx A, Simon-Keller K. 2019 Jun. CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma. Sci Rep. 9:9211.
   PubMed Web of Science ®Google Scholar
• Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, et al. 2016 Oct. Malignant melanoma-the cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol. 106:25–54.
   PubMed Web of Science ®Google Scholar
• Krug K, Mertins P, Zhang B, Hornbeck P, Raju R, Ahmad R, Szucs M, Mundt F, Forestier D, Jane-Valbuena J, et al. 2019 Mar. A curated resource for phosphosite-specific signature analysis. Mol Cell Proteomics. 18:576–593.
   PubMed Web of Science ®Google Scholar
• Kwiatkowska D, Kluska P, Reich A. 2019 Jun. Beyond PD-1 immunotherapy in malignant melanoma. Dermatol Ther (Heidelb). 9:243–257.
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Zhang C, Zhang C, Wang H. 2020 Mar. A signature of tumor immune microenvironment genes associated with the prognosis of nonsmall cell lung cancer. Oncol Rep. 43:795–806.
   Web of Science ®Google Scholar
• Liu J, Tan Z, He J, Jin T, Han Y, Hu L, Song J, Huang S. 2020 Oct. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value. Biosci Rep. 40(10):1–17.
   Google Scholar
• Maby P, Corneau A, Galon J. 2020. Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). Methods Enzymol. 632:339–368.
   Web of Science ®Google Scholar
• MacGregor HL, Sayad A, Elia A, Wang BX, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, et al. 2019 Dec. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. J Immunother Cancer. 31(7):357.
   Google Scholar
• Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002 Nov. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549–555.
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Koeffler HP. 2016. Maftools: efficient analysis, visualization and summarization of MAF files from large-scale cohort based cancer studies. BioRxiv.052662.
   Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. 2015 May. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 12:453–457.
   PubMed Web of Science ®Google Scholar
• Novy P, Quigley M, Huang X, Yang Y. 2007 Dec. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol. 15(179):8243–8251.
   Google Scholar
• Odunsi K. 2017 Nov. Immunotherapy in ovarian cancer. Ann Oncol. 1(28):viii1–viii7.
   Google Scholar
• Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ(R)): Patient Version. 2002. PDQ cancer information summaries. Bethesda (MD). https://pubmed.ncbi.nlm.nih.gov/26389375/.
   Google Scholar
• Palmirotta R, Silvestris E, D’Oronzo S, Cardascia A, Silvestris F. 2017 Sep. Ovarian cancer: novel molecular aspects for clinical assessment. Crit Rev Oncol Hematol. 117:12–29.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. 2015 Apr. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14:847–856.
   PubMed Web of Science ®Google Scholar
• Perales-Puchalt A, Wojtak K, Duperret EK, Yang X, Slager AM, Yan J, Muthumani K, Montaner LJ, Weiner DB. 2019 Feb. Engineered DNA vaccination against follicle-stimulating hormone receptor delays Ovarian cancer progression in animal models. Mol Ther. 6(27):314–325.
   Google Scholar
• Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, et al. 2020 Dec. Gemogenovatucel-T (vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 21:1661–1672.
   PubMed Web of Science ®Google Scholar
• Schwich E, Rebmann V, Horn PA, Celik AA, Bade-Doding C, Kimmig R, Kasimir-Bauer S, Buderath P. 2019 Aug. Vesicular-bound HLA-G as a predictive marker for disease progression in epithelial ovarian cancer. Cancers (Basel). 2:11.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. 2019 Jan. Cancer statistics, 2019. CA Cancer J Clin. 69:7–34.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005 Oct. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 25(102):15545–15550.
   Google Scholar
• Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, et al. 2020 Oct. Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE). Clin Cancer Res. 15(26):5411–5423.
   Google Scholar
• Tan B, Guo J, Wang L, Wang L, Gan X, Chen B. 2021 Apr. Expression and change of miR-199b-5p, s HLA-G in thyroid carcinoma. Exp Mol Pathol. 28(120):104643.
   Google Scholar
• Thomas ED, Meza-Perez S, Bevis KS, Randall TD, Gillespie GY, Langford C, Alvarez RD. 2016 Oct. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. J Ovarian Res. 27(9):70.
   Google Scholar
• Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao G, Yu M. 2020 Jul. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 15(147):423–439.
   Google Scholar
• Ullah M, Azazzen D, Kaci R, Benabbou N, Pujade Lauraine E, Pocard M, Mirshahi M. 2019 Mar. High expression of HLA-G in Ovarian carcinomatosis: the role of interleukin-1beta. Neoplasia. 21:331–342.
   Web of Science ®Google Scholar
• van Drongelen V, Holoshitz J. 2017 Aug. Human leukocyte antigen-disease associations in rheumatoid arthritis. Rheum Dis Clin North Am. 43:363–376.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen H, Chen X, Lin H. 2016 Jan. Expression of tumor-related macrophages and cytokines after surgery of triple-negative breast cancer patients and its implications. Med Sci Monit. 11(22):115–120.
   Google Scholar
• Wang W, Liu JR, Zou W. 2019 Jul. Immunotherapy in ovarian cancer. Surg Oncol Clin N Am. 28:447–464.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F, Kollmorgen G, Rueger R. 2016. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genom Proteom. 11–12(13):407–423.
   Google Scholar
• Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. 2013 Jan. Genomics of Drug Sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41:D955–D961.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, et al. 2013. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:2612.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Dai X, Fang W, Zheng Y, Zhang J, Liu Y, Gu D. 2020. Overexpression of microRNA-367 inhibits angiogenesis in ovarian cancer by downregulating the expression of LPA1. Cancer Cell Int. 20:476.
   Web of Science ®Google Scholar